Abbott Laboratories Receivables

Abbott Laboratories (ABL.DE) currently reports a receivables of $8.6B as of June 2026. That compares with $10B in the prior-year period — down 16.0% year over year. Use the charts on this page to explore Abbott Laboratories's receivables history and peer comparisons.

Abbott Laboratories's receivables decreased from $10B to $8.6B — a 16.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abbott Laboratories reported $8.6B in receivables as of June 2026. That compares with $10B in the prior-year period — down 16.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $8.6B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abbott Laboratories, and consider following ABL.DE for alerts when major investors trade the stock.

Abbott Laboratories is classified in the Healthcare sector. On receivables, it currently shows $8.6B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABL.DE with unrelated industries.